AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 4% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Mizuho Securities Reiterates Neutral Rating on Amgen (AMGN), PT $208, 'Lukewarm Lumakras ESMO Data'
September 12, 2022 9:44 AM EDTMizuho Securities analyst Salim Syed reiterated a Neutral rating and $208.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "And last night, we received the first part of detailed data from Amgen's Ph3 CB200 trial (Lumakras in 2L+ NSCLC). While we expect to receive the second part of detailed data later today, the first part showed (a) a decrease in ORR from 36% in CB100 to yesterday's 28%, (b) Gr3 liver enzyme elevations in about 10% of patients -- known... More
